FINAL ISSUE
December 2017

Generic vs Brand-Name Antipsychotics
For some antipsychotics, generic formulations may be less bioavailable and less efficacious than the brand-name product.

Can Lithium Decrease the Risk of Dementia?
In a study in Denmark, lithium exposure in drinking water was significantly lower in people with dementia than in controls.

Ketamine for Social Anxiety Disorder?
Preliminary data suggest that ketamine (Ketalar and others) may relieve anxiety.

Postpartum Depression: Experimental Treatment with a GABA Modulator
In a study of women with severe postpartum depression, brexanolone, a formulation of allopregnanolone, was associated with decreased depressive symptoms.

In Brief
Researchers Find Evidence of a Lymphatic System in the Brain

CME 2017
If you are interested in completing the Continuing Medical Education (CME) posttest and evaluation for 2017, please go to btpnews.com/cme.

2013-2017 Bound Volume
A 5-year bound volume with a cumulative index covering the years 2013 to 2017 is available for purchase. This volume is available on thumb drive only; no print version will be published.

Antipsychotics for First-Episode Schizophrenia
For patients with first-episode schizophrenia, second-generation antipsychotics have a broad array of side effects but differ little in efficacy.

Sweet Sorrow
This month's issue of the newsletter concludes our 40th year and marks the end of a journey.

Subscription Refunds
If you paid for a subscription past December 2017, you will receive a pro-rated refund check by the end of December. Starting December 15, 2017, a free downloadable zip file will be available at btpnews.com for all archives from 2000 to 2017.

About the BTP Newsletter

Our subscribers say BTP is…

"Very relevant, practical, and thought-provoking."

"About the only thing left without drug ads...objective and balanced."

"Succinct, readable, clear, timely and relevant!"

"Well written and scientifically sound."

Originating at the Massachusetts General Hospital and Harvard Medical School, Biological Therapies in Psychiatry has been a trusted resource for physicians for over 30 years. Described as "influential" by the Atlantic Monthly, this concise, four-page, monthly newsletter provides up-to-date information about the rapidly expanding field of psychotropic medications and other biological treatments for mental disorders.

From his perspective as an editor, teacher, investigator, and clinician, Alan J. Gelenberg, M.D., reviews the widespread literatures of science and clinical practice. Dr. Gelenberg distills the material most relevant for a busy practitioner and presents it each month with a balance of scientific curiosity, healthy skepticism, and clinical experience.

Dr. Gelenberg is Professor and Interim Chair of Psychiatry at Penn State, Hershey. Since 1987, Dr. Gelenberg has been Editor-in-Chief of the Journal of Clinical Psychiatry, and he recently chaired the workgroup that revised the American Psychiatric Association's major depressive disorder guidelines. Dr. Gelenberg has been on the faculty of Harvard Medical School, MIT, and the University of Arizona and has written numerous scientific articles and book chapters on mood disorders, depression, and schizophrenia. He is listed in the Best Doctors in America and America's Top Doctors and received the 1997 Exemplary Psychiatrist Award of the National Alliance for the Mentally Ill.

We offer both print and online subscriptions. Our web site provides subscribers with 24-hour access to archives as well as current issues. In addition, Continuing Medical Education credit is available for reading BTP. You can earn up to 12.0 hours in category 1 credit by answering questions in the December issue about topics covered during the year.